Casdin Capital’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-70,638
Closed -$39.6M 51
2020
Q4
$39.6M Hold
70,638
1.17% 22
2020
Q3
$49.4M Sell
70,638
-14,668
-17% -$11.4M 2.21% 13
2020
Q2
$67.4M Hold
85,306
3.99% 8
2020
Q1
$50.8M Buy
85,306
+10,422
+14% +$10.2M 5.39% 6
2019
Q4
$85.1M Buy
74,884
+27,599
+58% +$30M 7.83% 2
2019
Q3
$56.2M Buy
47,285
+18,528
+64% +$28.3M 5.82% 7
2019
Q2
$47.4M Buy
28,757
+1,158
+4% +$2M 4.43% 9
2019
Q1
$56.2M Buy
27,599
+2,123
+8% +$3.74M 6.18% 5
2018
Q4
$32.7M Buy
25,476
+5,558
+28% +$8.53M 5.6% 6
2018
Q3
$37.7M Buy
19,918
+4,478
+29% +$9.25M 4.58% 9
2018
Q2
$31.4M Buy
15,440
+4,246
+38% +$9.68M 4.39% 7
2018
Q1
$24.8M Hold
11,194
4.35% 12
2017
Q4
$25.8M Hold
11,194
6.29% 5
2017
Q3
$19.9M Buy
11,194
+6,176
+123% +$8.63M 5.62% 6
2017
Q2
$6.83M Buy
5,018
+3,049
+155% +$3.68M 2.53% 16
2017
Q1
$2.32M Sell
1,969
-4,400
-69% -$4.49M 1.37% 26
2016
Q4
$5.09M Buy
6,369
+1,737
+38% +$1.38M 4.2% 9
2016
Q3
$4.07M Sell
4,632
-4,825
-51% -$3.5M 3.29% 11
2016
Q2
$5.3M Buy
9,457
+193
+2% +$109K 5.28% 8
2016
Q1
$5.1M Buy
9,264
+1,544
+20% +$948K 5.85% 8
2015
Q4
$6.42M Buy
+7,720
New +$7.71M 5.67% 6

Other funds holding BLUE

Casdin Capital's BLUE Position: Q1 2021 in Review

Casdin Capital sold out of bluebird bio (BLUE) in Q1 2021, closing a stake of 70,638 shares — an estimated $39.6M sold.

Casdin Capital first reported a position in BLUE in Q4 2015 and held it in 21 quarters. The position peaked at $85.1M in Q4 2019. 229 funds tracked by Wall St. Rank hold BLUE as of Q1 2021.

  • Casdin Capital reported no remaining bluebird bio position as of Q1 2021 after selling out during the quarter.
  • Casdin Capital sold 70,638 bluebird bio shares in Q1 2021, an estimated $39.6M.
  • Casdin Capital first reported a position in bluebird bio in Q4 2015 and held it in 21 quarters.
  • Casdin Capital's bluebird bio position peaked at $85.1M in Q4 2019.
  • 229 funds tracked by Wall St. Rank held bluebird bio as of Q1 2021.

Based on Casdin Capital's 13F filing for Q1 2021, filed 17 May 2021.